To screen ETFs by asset class, performance, yield and more, check out the
View as an RSS Feed
View John Kinnucan's Comments
Alexza Pharmaceuticals Reiterated With An Outperform At JMP Securities
If ALXA have 26.4M cash, and considering milestones from Grupo Ferrer and from a future partner (which can change the picture) in the U.S., while the net loss is 7M, which should be reduced as they done with the regulatory fees and reduced costs through reductions of their workforce and suspended the development of few product candidates, they can fund operations into the first-second quarter of 2013.
I think there will be a run-up into PDUFA date and then sell-off following approval. But they have big potential.
Aug 12, 2012. 10:52 PM
Link to Comment
Xignite quote data
© 2014 Seeking Alpha